In the invention provides a WNT/β-catenin signal transduction inhibitor selected from (i) axitinib, (ii) pazopanib, (iii) orlistat, (iv) topotecan, (v) pharmaceutically effective substitution derivatives thereof, or (vi) pharmaceutically acceptable salts, or solvates or hydrates thereof, diastereoisomers, tautomers, enantiomers, and prodrugs and active metabolites thereof,for use in the treatment or prevention of a disease or condition in which WNT/β-catenin signal transduction is a contributing factor and for use in a method for the immunotherapy of a hyperproliferative or neoplastic disease or condition in a subject in which DCs are administered to the subject. The invention further provides an in vitromethod for diagnosing WNT/β- catenin dependent cancers, said method comprising (i) contacting a sample of cells from a test cancer with one or more of the WNT/β-catenin signal transduction inhibitors disclosed herein,and (ii) assessing the effects of said inhibitor on said sample.
